Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignant tumors
10.3760/cma.j.issn.1008-1372.2019.12.012
- VernacularTitle: 白蛋白结合型紫杉醇治疗晚期难治性恶性肿瘤的疗效及安全性
- Author:
Wenwen LI
1
;
Lei HAN
1
;
Zhiguo ZHANG
1
;
Li LI
1
;
Hongwei GUO
1
;
Pei XUN
1
;
Jian LUO
2
Author Information
1. Department of Oncology, Daxing Hospital of Capital Medical University, Beijing 102600, China
2. Department of Oncology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College (PUMC), Cancer Hospital, Beijing 100021, China
- Publication Type:Journal Article
- Keywords:
Albumin-bound paclitaxel;
Antineoplastic combined chemotherapy protocols;
Drug resistance, neoplasm
- From:
Journal of Chinese Physician
2019;21(12):1803-1807
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignant tumors.
Methods:Patients in advanced stage of cancer who had had drug-resistant relapse after receiving multiple-line treatment received chemotherapy with albumin-bound paclitaxel from May 2016 to April 2018 in Daxing Hospital of Capital Medical University. Their clinical data were collected to evaluate the treatment efficacy and safety profile.
Results:36 patients who had advanced treatment-resistent tumors with evaluable data were enrolled. Of 36 patients, 55.56% (20) had previously received chemotherapy with paclitaxel. The objective response rate (ORR) was 8.33%, the disease control rate (DCR) was 25.0%, the median progression free survival (PFS) was 106 days, and the median overall survival (OS) was 183 days. The main adverse reactions of grade 3-4 were hematological toxicity, including neutropenia [36.11% (13/36)], anemia and thrombocytopenia [5.56% (2/36) and 16.67% (6/36)] in patients without neutropenia fever. Adverse effects of 3-4 degrees related to non-hematologic toxicity were not observed.
Conclusions:Chemotherapy regimen with albumin-bound paclitaxel has certain efficacy for advanced malignant tumors resistant to multiple lines of therapy and the adverse effects could be generally tolerated.
